18th February 2008
                                                   
                             Eden Research Plc ("Eden Research" or "Eden")
                                                   
                     Successful completion of three year trial programme for  3AEY

Eden  Research  is  pleased  to  announce today it has successfully completed  its  three  year  trial
programme  for  3AEY.   Since  2005,  Eden  has conducted over  thirty  efficacy  trials  for  its  EU
registration programme using leading contract research organisation Eurofins Agrisearch.

The  data  collected has demonstrated that Eden's low environmental impact product 3AEY is  both  cost
effective  and efficacious when compared to established botrytis control market standards Rovral(tm) and
Scala(tm) on wine grapes.

More recently, in the 2007 programme work concentrated in two new areas:

     *   Commercial efficacy comparisons with popular new generation premium products Frupica(tm),
         Teldor(tm)and Switch(tm); and
     *   Testing on grapes destined for the valuable fresh/dessert market, where the appearance of the
         crop further affects potential financial returns.

The Results

Disease  control  -  In three efficacy trials conducted in Greece last season by Eurofins  Agrisearch,
Eden's  Botrytis control product 3AEY, used four times as a preventative treatment, showed outstanding
results  when  compared  with  a variety of established products applied at  commercially  recommended
doses:

    *   In two trials on dessert grapes it performed significantly better at reducing disease, than
        the established market standards iprodione (Rovral(tm)) and pyrimethanil (Scala(tm)); whilst
    *   In a trial on wine grapes, disease severity was reduced by over 92%, statistically identical
        to the increasingly popular new generation products, Frupica(tm)(mepanipyrim),
        Teldor(tm)(fenhexamid), and Switch(tm) (cyprodinil & fludioxonil), whilst under high disease
        pressure.

Fruit  quality - In the same three trials, when fruit quality was assessed, Eden product 3AEY produced
the  highest % of premium grade fruit in all cases, and the smallest fraction of  Class 2 (lowest
quality) fruit.

These  trends were particularly noticeable (and statistically significant) when compared  to  the  new
market  leaders Frupica(tm), Teldor(tm) and Switch(tm).  The out-turn of premium quality fruit  from 
the  3AEY treated  plots in this trial reached 38.5% at harvest, approaching double that of the three new
industry standards (which only achieved out-turns of 23.5%, 20.2% and 28.3% premium grade respectively).
Losses to the lowest grade (Grade 2) fruit were also much reduced when treated with 3AEY at 6%, compared
to 18.5%, 26.2% and 17.7% respectively with the standard treatments.

Commenting, Tim Griffiths Eden's CEO said:

"We feel that these exciting results will help our commercial partners to achieve a strong position in
the market for grape botrytis control products.

"The  data  suggests that 3AEY could become the product of first choice for commercial  growers,  with
improved  fruit  quality  reinforcing  our product's reliability  and  attractive  natural  ingredient
profile.

"We  therefore intend to implement further marketing studies in Southern Europe this year to reinforce
these data.  We intend to conduct further comparative studies to assist our marketing partners."

                                                 Ends

Tim Griffiths, Chief Executive, Eden Research plc
T: 01993 868844

Matthew Robinson, JM Finn Capital Markets Ltd
T : 020 7600 1658

Jonathon Brill/Caroline Stewart, Financial Dynamics
T: 020 7831 3113


About Eden Research plc

Eden  Research plc is a UK publicly listed company on the PLUS Market, specialising in the development
of agrochemical products and intellectual property through licensing and marketing agreements.

Eden  is focused on developing products for the agricultural sector through the application of terpene
chemistry  and  other  patented  environmentally friendly technologies.   Eden  is  currently  working
alongside   universities   and  partner  companies  in  developing  its  product   portfolio   towards
commercialisation.

For further information please visit www.edenresearch.com.



                                                                
Eden Research plc
Edenville (LSE:EDE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Edenville.
Edenville (LSE:EDE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Edenville.